LUMATEPERONE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LUMATEPERONE (LUMATEPERONE).
Lumateperone is an atypical antipsychotic with a unique mechanism of action: it acts as a 5-HT2A receptor antagonist, a dopamine D2 receptor antagonist, and a serotonin reuptake inhibitor. It also modulates glutamate via enhanced AMPA and NMDA receptor activity.
| Metabolism | Primarily metabolized by CYP3A4 and to a lesser extent by CYP2C8 and CYP2D6; undergoes glucuronidation and oxidation; active metabolite is lumateperone N-desmethyl. |
| Excretion | Approximately 80% of the dose is excreted in feces (as unchanged drug and metabolites) and about 11% in urine. Less than 1% is excreted as unchanged lumateperone in urine. |
| Half-life | Terminal elimination half-life is approximately 13 hours in the plasma, supporting once-daily dosing. Steady state is reached within 5–7 days. |
| Protein binding | Approximately 97.4% bound to plasma proteins, primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Apparent volume of distribution is about 4.7 L/kg (based on 60 kg), indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability is approximately 2–4% due to extensive first-pass metabolism. Food increases AUC by approximately 1.6-fold. |
| Onset of Action | Oral: Clinical effects are observed within 1–2 weeks of daily dosing, with some improvement noted as early as week 1 in clinical trials. |
| Duration of Action | Maintained over 24 hours with once-daily oral administration. The long half-life supports sustained therapeutic coverage. |
| Molecular Weight | 357.5 |
| Action Class | Atypical Antipsychotic |
42 mg orally once daily, taken with food and at least 240 mL of water, with a titration schedule: 42 mg daily for 7 days, then 21 mg twice daily thereafter.
| Dosage form | CAPSULE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (eGFR ≥30 mL/min). For severe renal impairment (eGFR 15-29 mL/min), dose reduction to 21 mg orally once daily. Not recommended in end-stage renal disease (eGFR <15 mL/min). |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose to 21 mg orally once daily. Child-Pugh Class C: not recommended. |
| Pediatric use | Safety and efficacy not established in pediatric patients; no approved dosing guidelines available. |
| Geriatric use | Use with caution due to increased sensitivity to hypotension and sedation. Initiate at 21 mg orally once daily for 7 days, then increase to 42 mg once daily if tolerated. Monitor for orthostatic hypotension and falls. |
| 1st trimester | Limited human data; animal studies show risk; avoid unless benefit outweighs risk. |
| 2nd trimester | Limited human data; use only if clearly needed. |
| 3rd trimester | Risk of extrapyramidal symptoms and/or withdrawal in neonates; avoid during third trimester. |
Clinical note
Comprehensive clinical and safety monograph for LUMATEPERONE (LUMATEPERONE).
| Placental transfer | Crosses placenta in animals; likely in humans due to low molecular weight. |
| Breastfeeding | Present in animal milk; no human data; consider risk of infant sedation and motor development effects. |
| Lactation Rating | L4 (Limited Data - Possibly Hazardous) |
■ FDA Black Box Warning
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Lumateperone is not approved for the treatment of patients with dementia-related psychosis.
| Common Effects | Somnolence, Sedation, Dry mouth, Dizziness, Nausea, Vomiting, Diarrhea, Constipation, Weight gain, Increased appetite, Fatigue, Akathisia, Extrapyramidal symptoms, Insomnia, Headache |
| Serious Effects | Increased mortality in elderly patients with dementia-related psychosis, Suicidal thoughts or behaviors, Neuroleptic malignant syndrome, Tardive dyskinesia, QT prolongation and torsades de pointes, Seizures, Stroke and transient ischemic attacks, Venous thromboembolism |
Known hypersensitivity to lumateperone or any excipients
| Precautions | Cerebrovascular adverse reactions in elderly with dementia, Neuroleptic malignant syndrome, Tardive dyskinesia, Metabolic changes (hyperglycemia, dyslipidemia, weight gain), Leukopenia and neutropenia, Orthostatic hypotension and syncope, Seizures, Potential for cognitive and motor impairment, QT prolongation |
Loading safety data…
| Teratogenic Risk | Teratogenic risk is not established; animal studies show no evidence of harm at doses up to 10 times the maximum recommended human dose. However, human data are insufficient to rule out risk. First trimester: limited data, risk cannot be excluded. Second and third trimesters: antipsychotics may cause extrapyramidal symptoms or withdrawal in neonates. Risk-benefit assessment recommended. |
| Fetal Monitoring | Monitor for maternal adverse effects including extrapyramidal symptoms, metabolic changes (glucose, lipids), and weight gain. In neonates, monitor for extrapyramidal symptoms, hypertonia, hypotonia, respiratory distress, and feeding difficulties. |
| Fertility Effects | No human data; in animal studies, no adverse effects on fertility were observed. Potential for prolactin elevation may theoretically impair fertility, but clinical significance is unknown. |
| Food/Dietary | Administer with food (at least 350 calories) to enhance absorption. Avoid grapefruit juice, as it may increase lumateperone plasma concentrations. No other food interactions are known. |
| Clinical Pearls | Lumateperone is a novel antipsychotic with serotonin 5-HT2A receptor antagonism, dopamine D2 receptor antagonism, and indirect glutamatergic modulation via phosphodiesterase 10A inhibition. It has a favorable metabolic profile with minimal weight gain, low extrapyramidal symptom risk, and no QTc prolongation. Dose adjustment is necessary in moderate hepatic impairment (Child-Pugh class B) — maximum dose is 21 mg. The drug is not recommended for use in severe renal impairment (CrCl <30 mL/min) or severe hepatic impairment. Onset of antipsychotic effect may be delayed; clinical improvement may take 2–4 weeks. Important: Lumateperone can cause somnolence; advise patients not to drive or operate machinery until they know how the drug affects them. It may also increase risk of falls in elderly patients with dementia-related psychosis (not approved for this use). |
| Patient Advice | Take this medication exactly as prescribed, usually once daily with food. Do not take double doses if you miss a dose—skip it and continue your regular schedule. · Avoid alcohol while taking lumateperone, as it can worsen dizziness and drowsiness. · Contact your doctor immediately if you experience any unusual muscle movements, especially of the face or tongue (possible tardive dyskinesia), fever, stiff muscles, confusion (neuroleptic malignant syndrome), or difficulty swallowing. · Lumateperone may cause sleepiness or lowered blood pressure upon standing. Rise slowly from sitting or lying positions to prevent falls. · Antipsychotics can increase blood sugar and cholesterol; your doctor will monitor these levels. Report excessive thirst, frequent urination, or increased appetite. · Do not stop taking the medication abruptly without consulting your doctor, as withdrawal symptoms may occur. |